💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Volanesorsen Sodium

CHEMBL3544989 Phase 4 Aprobado Oligonucleotide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Volanesorsen sodium is an antisense oligonucleotide that targets and degrades apolipoprotein C-III (apoC-III) mRNA in hepatocytes via RNase H-mediated cleavage, thereby reducing plasma apoC-III levels that normally inhibit lipoprotein lipase and VLDL clearance. It is approved in Europe for familial chylomicronemia syndrome (FCS), a rare condition of severe hypertriglyceridemia due to lipoprotein lipase pathway defects, reducing triglyceride levels and pancreatitis risk. Its subcutaneous administration provides sustained apoC-III suppression.

Mecanismo de acción

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Volanesorsen sodium is an antisense oligonucleotide that targets and degrades apolipoprotein C-III (apoC-III) mRNA in hepatocytes via RNase H-mediated cleavage, thereby reducing plasma apoC-III levels that normally inhibit lipoprotein lipase and VLDL clearance. It is approved in Europe for familial chylomicronemia syndrome (FCS), a rare condition of severe hypertriglyceridemia due to lipoprotein lipase pathway defects, reducing triglyceride levels and pancreatitis risk. Its subcutaneous administration provides sustained apoC-III suppression.

Binds to complementary mRNA sequences through Watson-Crick base pairing, modulating gene expression by promoting mRNA degradation via RNase H or altering pre-mRNA splicing.

Yes, Volanesorsen Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligonucleotide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3544989. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.